Marko J Pregel from 51 Thorndike St, Arlington, MA 02474, age 61

Marko Pregel Phones & Addresses

51 Thorndike St, Arlington, MA 02474
87 Milton St, Arlington, MA 02474 • 781 646-2742
56 Sacramento St, Cambridge, MA 02138
Boston, MA

Work

Company:

Pfizer inc.
Oct 2010
Position:

Senior principal scientist

Education

Degree:

Doctorates, Doctor of Philosophy
School / High School:

Queen's University
1985 to 1990
Specialities:

Organic Chemistry

Skills

Assay Development • Biochemistry • High Throughput Screening • Biotechnology • Drug Discovery • Elisa • Pharmaceutical Industry • Molecular Biology • In Vivo • Antibodies • Oncology • Cell Biology • Cystic Fibrosis • Enzyme Assays • R&D • Drug Development • Cell Culture • Lifesciences • Medicinal Chemistry • Purification • Immunology • In Vitro • Cancer • Drug Design • Genetics • Laboratory Automation • Protein Chemistry • Enzyme Kinetics • Biopharmaceuticals • Pharmacokinetics • Immunoassays • Pharmaceuticals • Science • Cell • Pharmacology • Lead Change • Monoclonal Antibodies • Lc Ms • Gpcrs • Drug Metabolism • Cell Based Assays • Tissue Culture • Hplc • Biomarkers • Team Management • Adme • Toxicology

Languages

French

Interests

Health

Industries

Pharmaceuticals

Us Patents

Tetrahydroisoquinoline Derivatives For Treating Protein Trafficking Diseases
view source
US Patent:

20050176761, Aug 11, 2005
Filed:

Dec 7, 2004
Appl. No.:

11/006042
Inventors:

Marko Pregel - Arlington MA, US
Bradford Hirth - Littleton MA, US
John Kane - Maynard MA, US
Shuang Qiao - San Diego CA, US
Jill Gregory - Acton MA, US
Lisa Cuff - Leominster MA, US
Assignee:

Genzyme Corporation - Cambridge MA
International Classification:

A61K031/4709
A61K031/47
US Classification:

514310000
Abstract:

Tetrhydroisoquinoline derivatives, pharmaceutical compositions comprising them and methods of treating disease are disclosed herein. The disclosed compounds are useful in the treatment and prevention of diseases mediated by chloride channel activity and/or protein trafficking, including, but not limited to, diseases associated with impaired mucociliary clearance such as cystic fibrosis, bronchitis, emphysema, and the like.

Novel Small Molecules With Selective Cytotoxicity Against Human Microvascular Endothelial Cell Proliferation
view source
US Patent:

20070254894, Nov 1, 2007
Filed:

Jan 9, 2007
Appl. No.:

11/651406
Inventors:

John Kane - Maynard MA, US
Bradford Hirth - Littleton MA, US
Christopher Yee - Needham MA, US
Mark Staveski - Taunton MA, US
Hans-Peter Biemann - Cambridge MA, US
Marko Pregel - Arlington MA, US
International Classification:

A61K 31/4709
A61K 31/497
A61P 9/00
C07D 215/38
C07D 243/08
C07D 401/14
C07D 413/14
US Classification:

514253060, 514314000, 540575000, 544128000, 544238000, 544353000, 544363000, 546171000
Abstract:

Disclosed herein are angiogenesis inhibitors represented by formula (I) or formula (II): The variables for formulas (I) and (II) are defined herein.

Resumes

Director And Research Project Leader

view source

Location:

Cambridge, MA

Industry:

Pharmaceuticals

Work:

Pfizer Inc. since Oct 2010
Senior Principal Scientist

Education:

Queen's University 1985 - 1990
Doctorates, Doctor of Philosophy, Organic Chemistry

Skills:

Assay Development
Biochemistry
High Throughput Screening
Biotechnology
Drug Discovery
Elisa
Pharmaceutical Industry
Molecular Biology
In Vivo
Antibodies
Oncology
Cell Biology
Cystic Fibrosis
Enzyme Assays
R&D
Drug Development
Cell Culture
Lifesciences
Medicinal Chemistry
Purification
Immunology
In Vitro
Cancer
Drug Design
Genetics
Laboratory Automation
Protein Chemistry
Enzyme Kinetics
Biopharmaceuticals
Pharmacokinetics
Immunoassays
Pharmaceuticals
Science
Cell
Pharmacology
Lead Change
Monoclonal Antibodies
Lc Ms
Gpcrs
Drug Metabolism
Cell Based Assays
Tissue Culture
Hplc
Biomarkers
Team Management
Adme
Toxicology

Interests: